AiBIOLOGICS has developed an Artificial Intelligence software with deep learning algorithms that significantly expedites and refines antibody discovery, diagnostic development, vaccine design and immunogenicity mapping.
AiBIOLOGICS is an Irish company and sister company of Vertebrate Antibodies Ltd (VAL), an emerging biotech company established and incubated by the University of Aberdeen.
AiBIOLOGICS and VAL work in synergy. Immunological data generated by VAL are used to create new AI models by AiBIOLOGICS. In turn, AI algorithms created by AiBIOLOGICS are validated in VAL laboratories.
AiBIOLOGICS through its various artificial intelligence and deep learning algorithms has been created to accelerate biotherapeutic, diagnostic and vaccine discovery as well as to offer immunogenicity solutions.
The company was established in Dublin due to the rich biotech ecosystem present in Ireland from where it intends to develop partnerships to drive biological discovery platforms.
Team
Dr Ayham Alnabulsi
Chief Executive Officer, Director, Co-founder
Strategic visionary and entrepreneur with extensive knowledge in medical genetics, immunology and mathematics.
Dr Abdo Alnabulsi
Chief Operating Officer
Abdo Alnabulsi brings a unique combination of scientific expertise in immunoassays development and validations, cancer pathology and programming.
Dr Tiehui Wang
Chief Data Scientist
Dr Tiehui Wang is a leading immunologist with a research focus on the regulation mechanisms of the immune system.
Oliver Meister
Legal Director
Oliver is a UK qualified solicitor who represents the main shareholder in AI Biologics and assists the company in legal and regulatory matters.
Marius Ionescu
AI and Software Engineering
Marius Ionescu has 20 years’ experience in computer related technologies spanning from operating systems, telecommunication, to software engineering.
Florentina Mihaila
ADMIN DIRECTOR
Florentina Mihaila, is a seasoned administrative director experienced in coordinating financial, legal, and HR teams in a number of international organisations over the past 20 years.
Dr Wei Pang
Dr Wei Pang (Associate Professor, Heriot-Watt University) is a computer scientist who is specialised in Bio-inspired Computing, Machine Learning, and Explainable AI.
Advisors
Prof Graeme Murray
Professor Murray is Regius Professor of Pathology and academic clinical speciality lead for Pathology at the University of Aberdeen.
Prof Chris Secombes
Professor Secombes (Emeritus Regius Chair of Natural History) is a renowned immunologist with a wealth of expertise on veterinary immunology and immunopathology.
Breakthrough Solutions
Diagnostic Solutions
AiBIOLOGICS offers in silico modelling to accelerate discovery and development of serology-based assays that will transform the sector, improving assay performance, reducing cost and lead production time.
Through identification of immunodominant sequences, expression on our peptide display technology and leveraging of AI technologies, we can create breakthrough solutions for diagnostic discovery.
Vaccine Candidates
AiBIOLOGICS software will accelerate the development of vaccines (e.g. subunit & peptide vaccines) subsequently offering significant safety advantages.
The software can also identify immune components that will support mucosal vaccines design and reduce allergy associated effects.
Immunogenicity Mapping
EpitopePredikt provides in silico screening for potential immunogenic signatures of biological drug candidates for clinical evaluations.
We can identify immunogenic profiles for the lead candidates to carry forward from preclinical and clinical trials, thus reducing the risk of failure due to immunogenicity issues and improving overall safety.
“Our unique technology uses artificial intelligence and deep learning models to provide breakthrough solutions that will revolutionise the fields of diagnostics, vaccine designs and therapeutics evaluation.”
Do you have a vaccine, diagnostic or antibody discovery project or are seeking immunogenicity solutions ? Please contact us for details.
Technology
Our EpitopePredikt technology is a game-changer for diagnostic, antibody and vaccine discovery providing higher performance capacity with adaptability, significant reduction in manufacturing cost and lead times.
EpitopePredikt’s deep learning will structure the algorithms in layers in order to create an “artificial neural network” that can provide intelligent solutions for biological design.
The combination of AiBIOLOGICS recombinant epitopes with our proprietary peptide display platform ensures highly sensitive and specific detection of antibodies from your sample. This discovery and display platform is adaptable to any disease, in any organism.
Deep Learning algorithms
Deep Learning is a branch of machine learning, a subfield of Artificial Intelligence. It involves constructing and training very “deep” neural networks for problem solving, such as making predictions and revealing hidden patterns from very complex problems.
Deep learning is one major reason for the rise of AI over the last 10 years, and it has become a main driving force for AI to be recognised and applied to various problems.
Deep learning is suitable capturing very complex spatial and temporal patterns from a huge amount of data, but recently deep learning has also been applied to those problems in which only sparse data are available.
Evolutionary computation techniques
Evolutionary computation is a subfield of artificial intelligence and is inspired by evolution in biology. In an evolutionary algorithm, there is a population of potential solutions for a real-world problem, and the population will undergo several iterations, each of which involves the applications of evolutionary operators to each individual in the population, such as selection, mutation, and cross-over so that the individuals improve their fitness (i.e., the quality of the solution) over time. Eventually a satisfactory solution will be generated.
Evolutionary computation as a generic problem solver can be applied to a wide range of optimisation problems, from optimising the job schedules, logistics, to optimising the parameters of existing AI models.
Latest news
Learn more about our current projects, company news and past use cases of our technology.
EpitopePredikt employed to develop novel, epitope based SARS-CoV-2 ELISA assay
In 2020, AiBiologics joined forces with leading scientists and clinicians from the University of Aberdeen, NHS Grampian and it’s partner company Verte
22 April, 2021Artificial Intelligence Technology in COVID-19 Project
Vertebrate Antibodies will utilise its proprietary AI and recombinant technologies to tackle Covid-19. Vertebrate Antibodies Ltd (VAL) is joining forc
03 December, 2020
Use of EpitopePredikt in Lyme disease diagnostics.
EpitopePredikt has been utilised in NorthTick EU project to improve the sensitivity and specificity of existing serological testing methods. Borrelia
25 November, 2020